404 related articles for article (PubMed ID: 38567308)
1. Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer.
McGrath MK; Abolhassani A; Guy L; Elshazly AM; Barrett JT; Mivechi NF; Gewirtz DA; Schoenlein PV
Front Endocrinol (Lausanne); 2024; 15():1298423. PubMed ID: 38567308
[TBL] [Abstract][Full Text] [Related]
2. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies.
Saatci O; Huynh-Dam KT; Sahin O
J Mol Med (Berl); 2021 Dec; 99(12):1691-1710. PubMed ID: 34623477
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer.
Li CL; Moi SH; Lin HS; Hou MF; Chen FM; Shih SL; Kan JY; Kao CN; Wu YC; Kao LC; Chen YH; Lee YC; Chiang CP
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142451
[TBL] [Abstract][Full Text] [Related]
4. Endocrine resistance: what do we know?
Miller TW
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714450
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
Viswanadhapalli S; Ma S; Sareddy GR; Lee TK; Li M; Gilbreath C; Liu X; Luo Y; Pratap UP; Zhou M; Blatt EB; Kassees K; Arteaga C; Alluri P; Rao M; Weintraub ST; Tekmal RR; Ahn JM; Raj GV; Vadlamudi RK
Breast Cancer Res; 2019 Dec; 21(1):150. PubMed ID: 31878959
[TBL] [Abstract][Full Text] [Related]
6. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
[TBL] [Abstract][Full Text] [Related]
7. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
Patel HK; Bihani T
Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.
Periyasamy-Thandavan S; Jackson WH; Samaddar JS; Erickson B; Barrett JR; Raney L; Gopal E; Ganapathy V; Hill WD; Bhalla KN; Schoenlein PV
Autophagy; 2010 Jan; 6(1):19-35. PubMed ID: 20110775
[TBL] [Abstract][Full Text] [Related]
9. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
10. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
[TBL] [Abstract][Full Text] [Related]
11. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
[TBL] [Abstract][Full Text] [Related]
12. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
Clarke R; Liu MC; Bouker KB; Gu Z; Lee RY; Zhu Y; Skaar TC; Gomez B; O'Brien K; Wang Y; Hilakivi-Clarke LA
Oncogene; 2003 Oct; 22(47):7316-39. PubMed ID: 14576841
[TBL] [Abstract][Full Text] [Related]
14. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
15. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.
Cook KL; Wärri A; Soto-Pantoja DR; Clarke PA; Cruz MI; Zwart A; Clarke R
Clin Cancer Res; 2014 Jun; 20(12):3222-32. PubMed ID: 24928945
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.
Johnston SR; Martin LA; Head J; Smith I; Dowsett M
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):173-81. PubMed ID: 15996863
[TBL] [Abstract][Full Text] [Related]
17. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
18. Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Augusto TV; Amaral C; Almeida CF; Teixeira N; Correia-da-Silva G
Mol Cell Endocrinol; 2021 Nov; 537():111426. PubMed ID: 34391846
[TBL] [Abstract][Full Text] [Related]
19. The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance.
Suba Z
Drug Des Devel Ther; 2015; 9():4341-53. PubMed ID: 26273195
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.
Zhang J; Wang Q; Wang Q; Cao J; Sun J; Zhu Z
Cell Mol Life Sci; 2020 Feb; 77(4):559-572. PubMed ID: 31471681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
